Nephrology News and Research

RSS

Nephrology is a branch of internal medicine and pediatrics dealing with the study of the function and diseases of the kidney.

Hidden incision endoscopic technique eliminates visible scarring in kidney surgery

Surgery and all its implications can be scary, especially so for pediatric patients and their parents who dread sometimes disfiguring scars.

2 Jul 2011

Avastin for breast cancer still covered by Medicare despite FDA indecision

The Medicare will continue to cover Avastin for breast cancer treatment even if U.S. Food and Drug Administration Commissioner Peggy Hamburg decides to withdraw Avastin for such use, according to Don McLeod, a spokesman for the Centers for Medicare and Medicaid. McLeod said, in his statement, “The FDA decision, when it comes, does not affect CMS.”

1 Jul 2011

Panel advises FDA to reject Avastin as breast cancer drug

The unanimous recommendation by this committee of cancer experts increases the likelihood that the drug will no longer be widely available for the treatment of breast cancer. Avastin, however, will continue to have the Food and Drug Adminstration's approval for use in treating certain other cancers.

1 Jul 2011

Diagnostic delay in women with tuberous sclerosis complex increases mortality risk

Women with tuberous sclerosis complex (TSC) are often misdiagnosed because the condition, commonly recognized in early childhood when it presents with seizures, manifests differently later in life, typically with renal angiomyolipomas - a benign tumor of the kidney - and pulmonary lymphangioleiomyomatosis (LAM) - a rare lung disease that affects almost exclusively women.

30 Jun 2011

STSI joins JAX consortium to develop targeted cancer therapies

The Scripps Translational Science Institute (STSI) of San Diego, Calif., has joined a national consortium of research institutions headed by The Jackson Laboratory (JAX) that is building a library of primary human tumors with the goal of developing highly targeted cancer therapies.

30 Jun 2011

Hemova device can reduce risk of infection, clotting and vessel narrowing in dialysis patients

Johns Hopkins University graduate students have invented a device to reduce the risk of infection, clotting and narrowing of the blood vessels in patients who need blood-cleansing dialysis because of kidney failure.

30 Jun 2011

Nuvilex to continue development of acquired live-cell encapsulation technology

Nuvilex, Inc. announced its plans to continue development of the live-cell encapsulation technology obtained with its recent acquisition of SG Austria, to carry out the pancreatic cancer clinical trial, to maintain and expand customers utilizing the encapsulation technology, and to establish itself as an active participant in the stem cell arena. The stem cell market was estimated to be $21.5 billion globally in 2010 and is forecast to reach $63.8 billion by 2015.

29 Jun 2011

U.Va. and Epsilon partner to provide commercial version of computer-based diabetes simulation tool

A computer-based diabetes simulation tool developed by University of Virginia researchers is now commercially available, thanks to a partnership with the Charlottesville-based medical research firm The Epsilon Group. The simulator is the only protocol that has been accepted by the U.S. Food and Drug Administration as an alternative to animal testing of Type 1 diabetes control strategies.

29 Jun 2011

Relypsa initiates dosing in RLY5016 Phase 2b trial for hyperkalemia in diabetic nephropathy and CKD patients

Relypsa, Inc. today announced the start of dosing in a Phase 2b clinical trial of RLY5016 for the treatment of hyperkalemia in patients with diabetic nephropathy and chronic kidney disease (CKD). RLY5016 is a high capacity, non-absorbed, polymer-based potassium binder that is orally administered and has been shown to control serum potassium levels in previous studies.

28 Jun 2011

FDA accepts Pfizer's filing for axitinib review for advanced renal cell carcinoma

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted Pfizer's filing for standard review of axitinib for patients with advanced renal cell carcinoma (RCC).

28 Jun 2011

Tissue-engineered blood vessels from donor skin cells successfully implanted in patients

For the first time, blood vessels created in the lab from donor skin cells were successfully implanted in patients. Functioning blood vessels that aren't rejected by the immune system could be used to make durable shunts for kidney dialysis, and potentially to improve treatment for children with heart defects and adults needing coronary or other bypass graft surgery.

28 Jun 2011

ChemoCentryx CCX140 Phase II study on type 2 diabetes meets primary endpoint

ChemoCentryx, Inc. today announced that CCX140, the Company's novel, orally active CCR2 antagonist successfully met its primary endpoint of safety and tolerability and demonstrated clinical efficacy in a Phase II study in patients with type 2 diabetes on stable doses of metformin.

28 Jun 2011

New strategies for minimising the consequences of preterm babies

Babies born prematurely could be at greater risk of developing kidney diseases later in life according to a landmark study investigating the impacts of preterm birth on kidney development.

28 Jun 2011

FDA directive on anemia drug in kidney disease patients

The U.S. Food and Drug Administration (FDA) has issued new warnings for anemia drugs for patients with kidney disease after studies suggested such drugs could increase stroke risks. The new warnings are the latest to hit the widely used medications since 2007, when the FDA first said they could cause fatal side effects.

27 Jun 2011

Chaos in biochemical alterations of cancer cells

Using the latest gene sequencing tools to examine so-called epigenetic influences on the DNA makeup of colon cancer, a Johns Hopkins team says its results suggest cancer treatment might eventually be more tolerable and successful if therapies could focus on helping cancer cells get back to normal in addition to strategies for killing them.

27 Jun 2011

FDA recommends conservative dosing guidelines for ESAs to treat anemia in patients with CKD

The U.S. Food and Drug Administration today recommended more conservative dosing guidelines for Erythropoiesis-Stimulating Agents (ESAs) when used to treat anemia in patients with chronic kidney disease (CKD) because of the increased risks of cardiovascular events such as stroke, thrombosis, and death.

27 Jun 2011

New anti-inflammatory drug improves kidney function in patients with type 2 diabetes

A new anti-inflammatory drug used by patients with type 2 diabetes improved their kidney function during a year-long study involving researchers from UT Southwestern Medical Center.

27 Jun 2011

New bardoxolone methyl Phase 2 trial data on kidney disease, diabetes presented at ERA-EDTA 2011

New Phase 2 clinical trial data published online today in The New England Journal of Medicine show that patients with moderate to severe chronic kidney disease and type 2 diabetes receiving bardoxolone methyl for 52 weeks experienced a sustained improvement in kidney function throughout the treatment period, as measured by estimated glomerular filtration rate.

27 Jun 2011

Mortality, morbidity rates linked with AF remain 'unacceptably high' despite new treatments

Despite recent advances in the treatment of heart rhythm disturbances, mortality and morbidity rates associated with atrial fibrillation (AF) remain "unacceptably high", according to a new report.

27 Jun 2011

UVA to study how the 'Call to Health' model helps African-American women manage diabetes

The University of Virginia Health System has received a $300,000 grant to study the "Call to Health" model, which uses text messages, stress reduction and other techniques to help African-American women manage type 2 diabetes.

27 Jun 2011

Nephrology News and Research

Further Reading

Hidden incision endoscopic technique eliminates visible scarring in kidney surgery

Avastin for breast cancer still covered by Medicare despite FDA indecision

Panel advises FDA to reject Avastin as breast cancer drug

Diagnostic delay in women with tuberous sclerosis complex increases mortality risk

STSI joins JAX consortium to develop targeted cancer therapies

Hemova device can reduce risk of infection, clotting and vessel narrowing in dialysis patients

Nuvilex to continue development of acquired live-cell encapsulation technology

U.Va. and Epsilon partner to provide commercial version of computer-based diabetes simulation tool

Relypsa initiates dosing in RLY5016 Phase 2b trial for hyperkalemia in diabetic nephropathy and CKD patients

FDA accepts Pfizer's filing for axitinib review for advanced renal cell carcinoma

Tissue-engineered blood vessels from donor skin cells successfully implanted in patients

ChemoCentryx CCX140 Phase II study on type 2 diabetes meets primary endpoint

New strategies for minimising the consequences of preterm babies

FDA directive on anemia drug in kidney disease patients

Chaos in biochemical alterations of cancer cells

FDA recommends conservative dosing guidelines for ESAs to treat anemia in patients with CKD

New anti-inflammatory drug improves kidney function in patients with type 2 diabetes

New bardoxolone methyl Phase 2 trial data on kidney disease, diabetes presented at ERA-EDTA 2011

Mortality, morbidity rates linked with AF remain 'unacceptably high' despite new treatments

UVA to study how the 'Call to Health' model helps African-American women manage diabetes

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News